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Infections caused by filamentous fungi represent a major burden in the ICU. Invasive aspergillosis is emerging in
non-neutropenic individuals with predisposing conditions, e.g. corticosteroid treatment, chronic obstructive pul-
monary disease, liver cirrhosis, solid organ cancer, HIV infection and transplantation. Diagnosis is challenging be-
cause the signs and symptoms are non-specific, and initiation of additional diagnostic examinations is often
delayed because clinical suspicion is low. Isolation of an Aspergillus species from the respiratory tract in critically
ill patients, and tests such as serum galactomannan, bronchoalveolar lavage 1–3-b-D-glucan and specific PCR
should be interpreted with caution. ICU patients should start adequate antifungal therapy upon suspicion of in-
vasive aspergillosis, without awaiting definitive proof. Voriconazole, and now isavuconazole, are the drugs of
choice. Mucormycosis is a rare, but increasingly prevalent disease that occurs mainly in patients with uncon-
trolled diabetes mellitus, immunocompromised individuals or previously healthy patients with open wounds
contaminated with Mucorales. A high proportion of cases are diagnosed in the ICU. Rapidly progressing necrotiz-
ing lesions in the rhino-sinusal area, the lungs or skin and soft tissues are the characteristic presentation.
Confirmation of diagnosis is based on demonstration of tissue invasion by non-septate hyphae, and by new
promising molecular techniques. Control of underlying predisposing conditions, rapid surgical resection and ad-
ministration of liposomal amphotericin B are the main therapeutic actions, but new agents such as isavucona-
zole are a promising alternative. Patients with mucormycosis receive a substantial part of their care in ICUs and,
despite advances in diagnosis and treatment, mortality remains very high.
Introduction
Fungal infections represent a major burden in the critical care set-
ting, incurring increased morbidity and mortality in a vulnerable
population. The ICU team faces the challenge of invasive mould in-
fections in both ‘conventional’ cases in neutropenic individuals but
also, increasingly, in non-neutropenic patients. Candida infections,
Aspergillus infections and mucormycosis caused by members of
the Mucorales order are the most common infections, each of
which requires a different diagnostic and therapeutic approach.
The purpose of this review is to provide a practical guide to the
basic aspects of mould infections (Aspergillosisand mucormycosis)
in the critical care setting.
Invasive aspergillosis
Invasive aspergillosis (IA) is an opportunistic infection that occurs
mainly among patients with haematological malignancies, most
notably during prolonged periods of neutropenia, but also in sub-
jects with solid tumours, critical illness or HIV/AIDS, and in those
who have undergone allogeneic stem cell transplantation or solid
organ transplantation.1,2 In recent years, however, IA has increas-
ingly been recognized as an emerging disease in non-neutropenic
individuals and in patients admitted to the ICU, even in the appar-
ent absence of a classic predisposing immunodeficiency.3–8
Although not uncommon in immunocompetent patients, the fea-
tures of IA in this setting differ substantially from those in neutro-
penic patients and its epidemiology, clinical characteristics,
outcomes and prognosis are not well known. The incidence of IA in
the ICU ranges from 0.3% to 5.8%4,5 with an overall mortality rate
of.80%.3,9
A number of recent case series and single-centre cohort reports
have documented the expansion of patient populations at risk for
IA beyond those groups conventionally regarded as high risk.
These include patients with COPD and other chronic lung or
connective tissue diseases requiring corticosteroid therapy, de-
compensated liver cirrhosis, and solid cancer with or without
treatment.10,11
Diagnosis of IA in non-neutropenic critically ill patients is chal-
lenging because the signs and symptoms are non-specific, and
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initiation of additional diagnostic examinations is often delayed
because clinical suspicion is low. Early diagnosis and timely thera-
peutic intervention require a high level of awareness and suspicion.
Rates of IA in ICUs vary in different regions of the world, likely due
to differences in the types of patients admitted to the ICU for treat-
ment and the environmental quality of the air. A greater under-
standing of the population at risk, and the spectrum of symptoms
caused by IA in non-neutropenic patients, may contribute to im-
proved outcomes for this potentially treatable disease.
Epidemiology
In the critical care setting, Aspergillus can be harboured in poorly
maintained ICU ventilation and water systems, as well as in vari-
ous types of equipment. However, it is difficult to discriminate be-
tween colonization and infection when IA is isolated from the
patient. An increased incidence of IA in the ICU has been docu-
mented, but with different rates among subsets of ICU patients.
A high prevalence (17%) of IA has been observed in a cohort of
67 patients with severe hospital-acquired pneumonia admitted to
the ICU.12 Among 40 critically ill patients with confirmed H1N1 in-
fluenza infection, 9 (23%) developed IA 3 days after ICU admis-
sion.13 Retrospective, autopsy-controlled studies have revealed
interesting results. Roosen et al. analysed causes of death in the
ICU and observed 15 cases of IA, 5 of which were undiagnosed be-
fore death, in a series of 100 autopsies.14 In a study comparing
neutropenic and non-neutropenic patients with a diagnosis of IA
over a 6 year period, Cornillet et al. found a mean number of
15 cases of IA per year, of which approximately one-half occurred
in the ICU.6 In an Italian study conducted in two mixed ICUs over
2 years, the incidence of IA was 0.2%, far lower than in other re-
ports from similar ICUs.15
Risk factors
Risk factors for IA in non-neutropenic patients admitted to the ICU
include prolonged treatment with corticosteroids before ICU ad-
mission, COPD, liver cirrhosis with prolonged ICU stay (.7 days),
solid organ cancer, HIV infection and lung transplantation.16–19
However, many of these factors are frequent among non-
neutropenic critically ill patients. One of the intriguing hypotheses
proposed to explain a depressed immune response in the appar-
ently immunocompetent patient with multiorgan dysfunction re-
lates to the biphasic response to sepsis in which the initial
hyperinflammatory phase is followed by relative immunoparalysis.
This latter process is characterized by neutrophil deactivation, and
may place the patient at risk for developing opportunistic infec-
tions such as IA.20 Immunosuppression has been described as a
late stage of the biphasic response to sepsis and multiple organ
failure syndrome.21
One of the most important risk factors for IA in non-
neutropenic patients is COPD.7 Patients with COPD are susceptible
to Aspergillus colonization of the lower tract of the respiratory air-
way, and under particular circumstances this may lead to invasive
infection.22 Patients with COPD present with alterations in lung
structure, impaired immunological response, reduced mucociliary
clearance and mucosal lesions. Moreover, they are prone to fre-
quent hospitalization, broad-spectrum antibiotic treatment and
invasive procedures. All these factors could explain the high
incidence of aspergillosis in COPD.7 Of note, patients with COPD are
frequently treated with corticosteroids and both inhaled and sys-
temic therapy have been described as a major risk factor for asper-
gillosis.23,24 Steroids can accelerate the in vitro growth of
Aspergillus spp. since both innate and acquired immune responses
are impaired.25 Vandewoude et al. defined a total daily dose
20 mg of prednisone or equivalent as a criterion for defining
cases of IA.26 Both compensated and decompensated cirrhosis
have been described as risk factors for IA, and impaired phagocyt-
osis has been proposed as a possible explanation for heightened
risk in these groups.27,28 Diabetes has been observed as another
risk factor for IA,26 possibly due to impaired innate and acquired
immunity caused by hyperglycaemia.29 Several authors have re-
ported alcoholism and malnutrition as other possible risk factors
for IA.26,30 Regarding environmental factors, the concentration of
Aspergillus spores in the air is another important factor and high
levels have been associated with individual cases and outbreaks in
ICUs.31 It may also be possible that strains of Aspergillus that pro-
duce high levels of elastase are associated with a higher risk of
invasion.32,33
Patients in the ICU are subjected to multiple therapies
(e.g. broad-spectrum antibiotics, mechanical ventilation) and/or
manoeuvres (e.g. insertion of central venous catheters), which
may affect the immunological defence system. Even though some
of these could contribute to patients’ risk status, additional factors
may be required for the development of IA.5,16,30
Clinical diagnosis and case definition
Clinical manifestations of IA (e.g. fever, cough, purulent sputum)
may initially be indistinguishable from bacterial bronchopneumo-
nia.34 Recovery of the same Aspergillus species from several re-
spiratory samples in the course of antibiotic-resistant pneumonia
in patients with relevant risk factors is clearly suggestive for a diag-
nosis of IA.10 It has therefore been proposed that isolation of an
Aspergillus species from the respiratory tract in critically ill patients
with risk factors (e.g. COPD after corticosteroid exposure, severe
underlying disease) and clinical features of pneumonia should indi-
cate a probable case of IA. The clinical significance of isolating
Aspergillus conidia in respiratory samples remains unclear, and dif-
ferentiating true infection from simple colonization can be difficult.
Therefore, once the fungus is detected in a respiratory sample, the
decision to start empirical antifungal treatment should be based
on the patient’s current clinical status and on the presence or ab-
sence of risk factors for the development of acute pulmonary
aspergillosis.
The presence of a persistent pulmonary infection despite
broad-spectrum antibiotics, or abnormal thoracic imaging by CT
scanning, together with one or more risk factors should trigger fur-
ther diagnostic exploration by the testing of respiratory secretions
and/or laboratory markers. Invasive infections in patients with
negative cultures might be supported by positive serological and
molecular markers such as galactomannan (GM) antigen testing
and Aspergillus PCR, which requires at least two sequential positive
samples. Radiological findings can be non-specific in non-
neutropenic patients, and of the typical imaging findings observed
in neutropenic patients, the air crescent sign is seen only in a small
proportion of cases, while the halo sign is very rarely observed. The
halo sign and air crescent sign have a high sensitivity (80%) and
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specificity (60%–98%) in thoracic CT scans of neutropenic pa-
tients.17,35 In non-neutropenic patients, a lower sensitivity
(5%–24%) has been reported in the literature.36,37 Bronchoscopy
manifestations are also non-specific in non-neutropenic patients,
with a lack of consistent features on endoscopy.37
The diagnosis of IA remains problematic. The lack of specific cri-
teria for diagnosing IA in non-neutropenic patients hampers timely
initiation of appropriate antifungal therapy and may therefore
compromise chances of survival.38–41 Recently Blot et al.42 exter-
nally validated a clinical diagnostic algorithm that aims to discrim-
inate colonization from probable IA in ICU patients with
Aspergillus-positive endotracheal aspirate cultures (Table 1).
Microbiological diagnosis
The microbiological diagnosis of aspergillosis can be achieved
using conventional and molecular approaches, including antigen
detection and PCR assays.43 Conventional culture methods are es-
sential for isolating and identifying the aetiological agent, while
identification is largely based on an accurate analysis of the
macro- and microscopic features of the colonies. Size, colour and
shape of the colony, microscopic visualization of conidiophores
and conidial heads, morphology, size and colour of the conidia are
important features for identifying the isolate at the species
level.43,44 More recently, DNA sequencing and the MALDI-TOF MS
proteomic approach have been shown to be useful tools to identify
non-sporulating isolates or isolates with atypical morphology.45–47
The Platelia Aspergillus enzyme immunoassay (Bio-Rad
Laboratories, Redmond, WA, USA) reveals the presence of GM, a
polysaccharide of the outer cell wall layer ofAspergillus, in patients
with suspected aspergillosis.43,48 GM can be detected in body
fluids, but serum levels in non-neutropenic patients appear to be
inaccurate, first because circulating neutrophils are able to clear
the antigen, and second, due to various causes for false-
positivity.40 Meersseman et al.49 demonstrated a high sensitivity
and specificity of GM in bronchoalveolar lavage (BAL) fluid for the
diagnosis of IA. Notably, the sensitivity of BAL GM was 88%, in con-
trast to 40% for serum GM. GM detection in BAL is therefore a valu-
able tool for the diagnosis of IA in non-neutropenic patients.49
Therapeutic approaches
Prompt and appropriate antifungal therapy is of critical importance
for limiting the mortality rate from IA in ICU patients, which ranges
between 60% and 90%.16 Hence, patients without classic risk fac-
tors (i.e. COPD, steroids and immunosuppressive therapy, hepatic
failure, ICU-related immunoparalysis) should start adequate anti-
fungal therapy upon suspicion of IA, before obtaining definitive
proof of infection. Early initiation of first-line therapy, at the stage
of possible infection, was reported to improve outcomes in a retro-
spective analysis of factors predicting mortality in a series of
289 patients with possible, probable or proven IA.50 However,
high-quality studies specifically in ICU populations are generally
lacking, and data from non-ICU settings is often the basis for treat-
ment decisions, as discussed in the article ‘New pharmacological
opportunities for the treatment of invasive mould diseases’ in this
Supplement.51
In contrast to patients with febrile neutropenic episodes, there is
no consensus about the exact time frame for starting empirical
therapy, without any diagnostic support, in other categories of crit-
ically ill patients at risk of IA.52 In a 6 year French survey, non-
neutropenic patients with IA were less likely to exhibit symptoms
suggestive of the disease but the sensitivity of microbiological sam-
pling, antigenaemia and thoracic CT findings were similar to those
Table 1. Clinical algorithm for the diagnosis of IA in non-neutropenic patients in the ICU42
Category Host factor Clinical presentation Mycological evidence
Proven
IA
• Not required • Not required • Pathology evaluation showing compatible
hyphae and associated tissue damage
and
• Culture showing Aspergillus in specimen obtained by
a sterile procedure from a normally sterile site
Probable
IA
At least one of the following:
• Glucocorticosteroid treatmenta
• Neutrophil abnormalityb
• Chronic airway abnormalityc
• Decompensated cirrhosis
• Treatment with recognized
T-cell immunosuppressantd
• Haematological malignancies/HSCT
• Solid organ transplantation
• HIV
• Severe influenza
• And clinical or radiological
abnormalities consistent with a
pulmonary infectious disease process
that are otherwise unexplained
At least one of the following non-definitive tests:
• Cytology, direct microscopy and/or culture showing
Aspergillus species in a lower respiratory tract specimen
• GM in serum0.5 and/or in BAL0.8
GM, galactomannan; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis.
aGlucocorticosteroid treatment with prednisone equivalent of20 mg/day.
bInherited neutrophil deficiency, absolute neutrophil count of500 cells/mm3.
cChronic obstructive lung disease, bronchiectasis.
dCalcineurin or mTOR inhibitors, blockers of TNF and similar antifungal immunity pathways, alemtuzumab, nucleoside analogues during past 90 days.
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seen in neutropenic hosts.6 Therefore, a pre-emptive approach in
non-neutropenic patients, based upon microbiological biomarkers
(GM, Aspergillus PCR and 1,3-b-D-glucan assay, as a screening strat-
egy), may be helpful and should be implemented early for prompt
detection and treatment of invasive fungal infections in the ICU.11
Three classes of antifungal agents are available for the treatment
of IA: azoles (isavuconazole, voriconazole, posaconazole, itracon-
azole), amphotericin B and echinocandins (Table 2). Current guide-
lines recommend voriconazole as first-line treatment for IA,
including for critically ill patients in whom intravenous administration
is preferable.53 During the last 10 years, voriconazole use has pro-
gressively become widespread. A key study driving the adoption of
voriconazole was a randomized controlled trial published in 2002, in
which 277 patients with IA, mainly affected by haematological dis-
eases, showed significantly higher survival rates and fewer severe
adverse events with voriconazole versus amphotericin B.54 A large
retrospective cohort study investigating risk factors and outcomes in
ICU patients with IA (excluding those with classic risk factors)
showed that a 1 day delay in starting effective antifungal therapy
was associated with a mean of 1.28 days longer stay and a 4% in-
crease in total costs per day (P,0.001).55 Voriconazole was the
most frequent antifungal prescribed and its use appeared to improve
these outcome measures.55 Itraconazole is considered a second-
line agent for the treatment of IA, particularly in severely ill patients.
Use of oral itraconazole in non-life-threatening infections where the
patient has been already stabilized with a more potent agent has
been described.56 Posaconazole is a broad-spectrum triazole with
anti-Aspergillus activity similar to that of voriconazole but limited
clinical experience, and (until recently) the absence of intravenous
formulations has reduced its applicability in critically ill patients.
Isavuconazole, a new triazole agent, can be given once-daily
and offers a wider spectrum of antifungal activity than voricon-
azole, including activity against most Mucorales infections. A large
randomized, double-blind trial has demonstrated non-inferiority
for isavuconazole versus voriconazole in terms of all-cause mortal-
ity when used as primary treatment for invasive fungal disease
caused byAspergillus species or other filamentous fungi, with a su-
perior safety profile.57
Before the introduction of voriconazole, amphotericin B was the
mainstay of treatment for IA. Development of lipid formulations
improved the poor tolerability associated with the deoxycholate
formulation, but the optimal dosage remains unconfirmed.58
High-dose liposomal amphotericin B (10 mg/kg/day) does not im-
prove outcomes but may increase nephrotoxicity.59
All echinocandins have been shown to exert in vitro and in vivo
activity against Aspergillus spp. but only caspofungin is approved for
the treatment of IA, in patients who are intolerant to first-line ther-
apy. Although still not approved, the other two echinocandins (ani-
dulafungin and micafungin) are used in clinical practice, particularly
when non-neutropenic patients are involved. In breakthrough IA
and in refractory disease, combination therapy (e.g. echinocandin
plus voriconazole or liposomal amphotericin B) may be considered.
Outcome and prognostic factors
Only a small number of clinical studies have investigated the out-
come of IA in critically ill patients. Different studies are difficult to
compare due to the absence of specific clinical signs, variations in
diagnostic criteria and inconsistency with which coexisting diseases
are recognized as risk factors.16 Mortality rates also vary. The overall
mortality rates for IA are 17%, based on US national data, but
mortality is higher in cases of Aspergillus pneumonia or in immuno-
compromised patients with IA.59 Specifically, mortality rises to 25%
in Aspergillus pneumonia, while in patients with blood or lymphoid
tissue malignancies, bone marrow transplant recipients or liver
transplant recipients, mortality rates in IA are 49%, 80% and 90%,
respectively.59 It should be noted that the immune status of critic-
ally ill patients, as well as other underlying conditions, are import-
ant determinants of the type of fungal infection that may develop,
and for immunodeficient patients the infection is usually invasive.
Thus, patients receiving steroids are at increased risk of developing
cavitating lesions and aspergillomas. In a retrospective analysis of
fungal infections in non-neutropenic patients, Garbino et al.60
showed a mortality rate of 57.1% for patients with IA.
Various studies have examined prognostic factors, but isolation
of Aspergillus in critically ill patients is associated with high mortal-
ity, irrespective of invasion or colonization.11 Overall, it appears
that the mortality rate in IA is significantly higher in non-
neutropenic patients than in neutropenic individuals.
Mucormycosis
Mucormycosis is a fungal infection caused by different fungi of the
order Mucorales, not only by those belonging to the genus Mucor. In
Table 2. Treatment of IA in non-neutropenic patients in the ICU
Setting First choice Alternatives
Primary therapy Voriconazole (6 mg/kg q12h iv
on day 1, then 4 mg/kg q12h iv)
or
Isavuconazole (initial dose 372 mg q8h
po or iv%6 doses for 48 h; maintenance
dose 372 mg/day po or iv)
Liposomal amphotericin B
(3–5 mg/kg/day iv)
or
Posaconazole (300 mg iv bid on day 1,
then 300 mg/day iv)
or
Caspofungin 70 mg loading
dose, then 50 mg/day
Salvage therapy Combination of voriconazole plus anidulafungin
bid, twice a day; iv, intravenous; po, per os (orally); q8h, every 8 h; q12h, every 12 h.
Bassetti and Bouza
i42
1978, Agger and Maki first drew attention to mucormycosis as a
complication of critical care, reporting three previously non-
immunocompromised patients who developed mucormycosis after
treatment with steroids and antibiotics.61 It is an uncommon but
very severe disease, progressively reported in the last 20 years, and
a high proportion of cases are diagnosed or treated in ICUs.62–65
Epidemiology
In a population-based study carried out in Spain in 2005, the rate
of mucormycosis was 0.43 cases/1 000 000 inhabitants and
0.62 cases/100 000 hospital admissions.66 In France, cases
increased from 0.7/million inhabitants in 1997 to 1.2/million inhab-
itants in 2006.67 In a tertiary care centre in India, the number of
cases per year increased from 13 in 1990–99 to 50 in 2006–07.68
Other reports have also indicated an increase of mucormycosis in
recent years.69,70 Epidemiological data specifically related to the
ICU are lacking, but mucormycosis is frequently reported as indi-
vidual case reports or as small series in ICUs.62,65,71 The analysis of
data from one centre found that 37% of mucormycosis cases
were diagnosed in patients treated in the ICU (Emilio Bouza,
CIBERES, personal communication).
Risk factors
Mucormycosis occurs mainly, but not exclusively, in immunocom-
promised patients with haematological malignancies, solid organ
transplant recipients and patients with other immunodeficiencies,
as well as in patients with diabetes mellitus. It can also occur fol-
lowing trauma or invasion of wounds covered with contaminated
dressings, e.g. in the ICU. One outbreak of gastric mucormycosis in
ICU patients reported in Spain arose in association with the use of
contaminated wooden tongue depressors in critically ill patients.72
Clinical diagnosis and case definition
Manifestations of pulmonary mucormycosis are frequently fever
and unresolving pulmonary infiltrates, despite the use of broad-
spectrum antibiotics.73,74 Respiratory mucormycosis may involve
the lung parenchyma and the pulmonary vascular system but also
the bronchial tree and trachea.75 Radiological signs of pulmonary
mucormycosis may be indistinguishable from those of IA or from
neoplastic or inflammatory diseases. Ring-halo signs with air
crescents may be indicative of mucormycosis in chest CT. The util-
ity of positron emission tomography or CT scanning is still not de-
finitively established but preliminary data shows uptake of
[18F]fluorodeoxyglucose76,77 in invasive fungal infections.
Rhino-cerebral mucormycosis remains an important clinical
presentation of mucormycosis, particularly in Asia and in patients
with diabetes mellitus. Necrosis evolves rapidly, although cases of
chronic slowly evolving lesions in immunocompetent hosts are oc-
casionally reported.78 Mucormycosis complicating wound infections
or other skin lesions, including intravenous needle punctures, is well
known and should be suspected in the presence of progressive ne-
crosis of any extent. These may occur in traumatic wounds in com-
pletely immunocompetent hosts, such as patients in the ICU,67,79
but also in immunocompromised patients of different types. In a
European series reported by Skiada et al.80 the most common mani-
festations of mucormycosis were pulmonary (30%), rhino-cerebral
(27%), soft tissue (26%) and disseminated disease (15%).
Microbiological diagnosis
As discussed in ‘Early diagnosis of mould infections and disease’ in
this Supplement,81 the detection of both GM and 1–3-b-D-glucan is
futile in mucormycosis because Mucorales do not produce these
biomarkers.82 A recently reported technique consists of quantify-
ing Mucorales DNA in serum by PCR. It combines three quantitative
PCRs to identify Mucor/Rhizopus, Lichtheimia and Rhizomucor83,84
and can be positive many days before the appearance of common
clinical manifestations. Confirmation of the utility of this technique
will require experience in a larger series of cases.
However, confirmation of the diagnosis requires a positive cul-
ture from tissues that are ordinarily sterile, based on samples that
have been obtained under sterile conditions. The combination of a
clinically compatible setting with positive clinical samples obtained
from non-sterile samples, such as respiratory secretions, makes
the diagnosis only probable.85 Tissue biopsy is essential, and the
presence of broad, non-septate hyphae invading the tissues and
vessels, with right angles and a ribbon-like appearance, is ad-
equate to confirm the diagnosis.86 In the case of pulmonary infec-
tions, samples may be obtained by open pulmonary resection but
also by transthoracic CT-guided procedures and, in the case of
rhino-cerebral forms, by samples obtained through nasal endos-
copy.87–89
Samples must be approached carefully in the clinical microbiol-
ogy laboratory and should not be triturated in preparation for cul-
ture. Alternatively, direct small fragments obtained with a scalpel
can be examined and cultured to obtain a better yield. Calcofluor
white examination is highly recommended, followed by culture
and species identification. MALDI-TOF is currently a useful alterna-
tive to conventional methods for species identification,90,91 as are
molecular techniques performed either on isolates or in tissue
samples.92–94 Finally, antimicrobial susceptibility testing of anti-
fungal agents against Mucorales isolates is an important part of
the responsibilities of the microbiology laboratory.95,96 Mucor iso-
lates are largely susceptible to amphotericin B, posaconazole and
isavuconazole, but not to fluconazole, voriconazole or candins.
Therapeutic approaches
Rapid application of treatment measures in mucormycosis is asso-
ciated with reduced mortality.97–101 Management strategies are
similar for patients treated in the ICU or elsewhere (see ‘New
pharmacological opportunities for the treatment of invasive mould
diseases’ in this Supplement).51 Three interventions must be com-
bined: correction of underlying conditions where feasible, surgical
resection when possible and antifungal therapy.
Regarding the underlying conditions, the correction of hypergly-
caemia in diabetic patients, the reversal of ketoacidosis, and taper-
ing of corticosteroids and immunosuppressive agents are among
the recommended measures. Shortening the duration of neutro-
penia by granulocyte colony-stimulating factor is also recom-
mended by ESCMID and the European Conference on Infections in
Leukaemia86,102 but the level of evidence demonstrating efficacy
is minimal.
Surgery is a key element in the management of mucormycosis,
particularly for rhino-cerebral forms and for mucormycosis of skin
and soft tissues. Repeated surgical intervention is frequently ne-
cessary to achieve surgical control, with sequential resections.
The role of surgery is less clear for pulmonary mucormycosis in
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patients with haematological conditions and should be decided
on an individual basis in patients with disseminated disease.
Overall, surgery associated with antifungal agents improves mor-
tality rates compared with medical treatment alone and is benefi-
cial even when full resection of necrotic invaded tissue cannot be
achieved.76,102–107
The role of specific drugs in the treatment of mucormycosis is
described in ‘New pharmacological opportunities for the treatment
of invasive mould diseases’ in this Supplement.51 In brief, lipid for-
mulations of amphotericin B, and particularly liposomal ampho-
tericin B, are presently the mainstay of antifungal treatment of
mucormycosis. Posaconazole is active in vitro against Mucorales
and is considered a second-line drug, recommended for salvage
therapy. Isavuconazole is a new triazole derivative, which is ac-
tive against moulds of the order Mucorales, with better tolerance
than amphotericin B, and can be used for the treatment of
mucormycosis.
Other treatments
The use of adjunctive iron chelators, such as deferasirox or deferi-
prone, is still associated with contradictory data and, at present,
neither agent is recommended as adjunctive treatment.108,109 The
use of hyperbaric oxygen is not currently recommended for routine
use. It may be beneficial in rhino-cerebral forms in diabetic pa-
tients but is less clearly of benefit in haematological patients with
pulmonary forms of the disease.86,102,110
Outcome and prognostic factors
Data regarding outcomes specifically relating to mucormycosis in
the ICU are not available, but despite recent advances in diagnosis
and treatment, the overall mortality associated with mucormyco-
sis is estimated to be between 22% and 59%80,111–115 depending
on the location and extent of the disease, underlying condition of
the patient and the speed in which proper treatment is
administered.99
Conclusions
Invasive filamentous fungal infections are very severe infections
that may be acquired in the ICU or, when acquired elsewhere, may
require critical care. Their diagnosis and management represents a
challenge for clinicians. The two main infections are IA and mucor-
mycosis, which may occur as non-resolving pneumonias or as
invasive extrapulmonary infections, particularly in skin and soft tis-
sue, rhino-sinusal regions or other areas. The complex underlying
conditions in these patients and the non-specific nature of symp-
toms can confound identification and lead to underdiagnosis.
Isolation of Aspergillus or Mucorales in clinical samples may be in-
sensitive or non-specific and the confirmation by biopsies showing
tissue invasion is not always feasible. Indirect, non-tissue based,
diagnostic tests are still in development and cannot yet provide a
rapid, conclusive diagnosis or exclude these infections in most situ-
ations. Voriconazole, amphotericin B and isavuconazole are the
drugs of choice for the treatment of IA, whilst amphotericin B,
posaconazole and isavuconazole are the main treatments for
mucormycosis, with proper surgical resection and correction of
underlying predisposing conditions where feasible. In spite of
technological advances, very high mortality rates persist in both IA
and mucormycosis.
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